|Articles|November 15, 2002
Efalizumab Lifts Quality of Life in Just Two Weeks
Winston-Salem, N.C. - After subcutaneous treatment with efalizumab(Raptiva), patients who achieved 50 to 75 percent improvement in PsoriasisArea and Severity Index (PASI) score reported improvement in quality oflife.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Karan Lal, DO, Shares Evolving Perspective on GLP-1 Agonists in Dermatology at SDPA Fall 2025
2
Dermatology Times Hosts 2025 Horizons in Advanced Practice Meeting
3
Nemolizumab Demonstrates Strong Efficacy in PN
4
Q&A: Treating Vitiligo in Difficult Sites Requires Patience and Precision
5















